Juan Morote

List of Publications by Year in descending order

249 papers	5,518 citations	94433 37 h-index	110387 64 g-index
266 all docs	266 docs citations	266 times ranked	6373 citing authors

#	Article	IF	Citations
1	A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy. European Urology Oncology, 2022, 5, 460-463.	5.4	13
2	The current recommendation for the management of isolated highâ€grade prostatic intraepithelial neoplasia. BJU International, 2022, 129, 627-633.	2.5	4
3	Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions. European Urology, 2022, 81, 124-125.	1.9	4
4	Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy. World Journal of Men?s Health, 2022, 40, 74.	3.3	6
5	The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer. World Journal of Men?s Health, 2022, 40, 270.	3.3	8
6	Re: Magdalena GÃ¶rtz, Jan Philipp Radtke, Gencay Hatiboglu, et al. The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies. Eur Urol Focus 2021;7:325â€“31. European Urology Focus, 2022, , .	3.1	1
7	The importance of appropriate castrate level measurements of serum testosterone in prostate cancer patients. Radiotherapy and Oncology, 2022, , .	0.6	0
8	Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category. European Urology Open Science, 2022, 37, 38-44.	0.4	5
9	DefiniciÃ³n de continencia y factores pronÃ³sticos para la recuperaciÃ³n temprana de la continencia urinaria en la prostatectomÃa radical robÃ³tica con reconstrucciÃ³n posterior del rabdoesfÃnter. AnÃ¡lisis post hoc de un ensayo clÃnico aleatorizado. Actas UrolÃ³gicas EspaÃ±olas, 2022, 46, 159-166.	0.7	3
10	Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?. International Journal of Biological Markers, 2022, 37, 218-223.	1.8	2
11	The Barcelona Predictive Model of Clinically Significant Prostate Cancer. Cancers, 2022, 14, 1589.	3.7	13
12	Continence definition and prognostic factors for early urinary continence recovery in posterior rhabdosphincter reconstruction after robot-assisted radical prostatectomy. Post-hoc analysis of a randomised controlled trial. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2022, , .	0.2	0
13	Definition of Castrate Resistant Prostate Cancer: New Insights. Biomedicines, 2022, 10, 689.	3.2	18
14	Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer. Cancers, 2022, 14, 1828.	3.7	5
15	Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review. BMC Cancer, 2022, 22, 357.	2.6	0
16	Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic Review. Molecular Diagnosis and Therapy, 2022, 26, 273-281.	3.8	7
17	Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy. Cancers, 2022, 14, 2374.	3.7	1
18	Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI. Cancers, 2022, 14, 2702.	3.7	2

#	Article	IF	Citations
19	The True Utility of Predictive Models Based on Magnetic Resonance Imaging in Selecting Candidates for Prostate Biopsy. European Urology Open Science, 2022, 42, 40-41.	0.4	1
20	Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. Journal of Urology, 2021, 205, 343-345.	0.4	0
21	Nuclear and cytosolic pS727-STAT3 levels correlate with overall survival of patients affected by clear cell renal cell carcinoma (ccRCC). Scientific Reports, 2021, 11, 6957.	3.3	4
22	Are Multiparametric Magnetic Resonance Imaging and Guided Biopsies Needed in Men with Normal Digital Rectal Examination and Prostatic-specific Antigen >20â€‰ng/ml?. European Urology Oncology, 2021, 4, 334-335.	5.4	1
23	The position of urethrovesical anastomosis after robotic radical prostatectomy assessed by MRI predicts early functional recovery: A cohort analyses from a randomized clinical trial. European Journal of Radiology, 2021, 137, 109589.	2.6	4
24	Valor actual de los hallazgos histolÃ³gicos de biopsias de prÃ³stata negativas en la prediccIÃ³n del riesgo futuro de cÃ¡ncer de prÃ³stata clÃnicamente significativo. Actas UrolÃ³gicas EspaÃ±olas, 2021, 45, 447-454.	0.7	2
25	The current value of histological findings in negative prostate biopsies to predict the future risk of clinically significant prostate cancer. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2021, 45, 447-454.	0.2	0
26	Alternating Cystoscopy with Bladder EpiCheckÂ® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. Bladder Cancer, 2021, 7, 307-315.	0.4	3
27	Reply to Nikolaos Kalampokis, Nikolaos Grivas, Markos Karavitakis, and Henk van der Poela€™s Letter to the Editor re: Aina Salazar, Lucas Regis, Jacques Planas, et al. A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2021.02.005. European Urology Oncology, 2021, , .	5.4	1
28	Papel del antÃgeno prostÃ¡tico especÃfico ante las nuevas evidencias cientÃficas, una nueva actualizaciÃ³n en 2020. Actas UrolÃ³gicas EspaÃ±olas, 2021, 45, 21-29.	0.7	5
29	The role of prostate-specific antigen in light of new scientific evidence: An update in 2020. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2021, 45, 21-29.	0.2	1
30	Surgeon preimplantation macroscopic graft appraisal improves risk stratification of deceased kidney donors: a prospective study. Minerva Urology and Nephrology, 2021, , .	2.5	4
31	Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples. Cancers, 2021, 13, 6202.	3.7	8
32	Re: Lars Boesen, Nis NÃ¸rgaard, Vibeke LÃ¸gager, et al. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7â€“10 Prostate Cancer in Biopsy-naÃ¯ve Men. Eur Urol Oncol 2019;2:311â€“9. European Urology Oncology, 2020, 3, 392-393.	5.4	2
33	Comparison of standard vs. palliative management for bladder cancer in patients older than 85 years: multicenter study of 317 de novo tumors. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 40.e9-40.e15.	1.6	6
34	How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies. World Journal of Urology, 2020, 38, 1481-1491.	2.2	6
35	Assessing the Clinical Benefit of UBC Rapid in the Surveillance and Initial Diagnosis of Bladder Cancer. Clinical Genitourinary Cancer, 2020, 18, 230-235.	1.9	3
36	Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review. BMC Urology, 2020, 20, 99.	1.4	6

#	Article	IF	Citations
37	Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer. Scientific Reports, 2020, 10, 20135.	3.3	4
38	Prediction of clinically significant prostate cancer after negative prostate biopsy: The current value of microscopic findings. Urologic Oncology: Seminars and Original Investigations, 2020, 39, 432.e11-432.e19.	1.6	0
39	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Nonâ€“Muscle-Invasive Bladder Cancer. Cancer Research, 2020, 80, 4476-4486.	0.9	49
40	The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. Cancer Treatment Reviews, 2020, 86, 102000.	7.7	19
41	Analysis of the nuclear expression of pSer727-STAT3 as a prognostic factor in patients with clear cell renal carcinoma. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2020, 44, 245-250.	0.2	0
42	Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2020, 44, 156-163.	0.2	0
43	Re: Frank-Jan H. Drost, Daniel Osses, Daan Nieboer, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. Eur Urol 2020;77:78â€“94. European Urology, 2020, 77, e138-e139.	1.9	5
44	Prostatic-specific antigen density behavior according to multiparametric magnetic resonance imaging result. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 410-417.	1.6	10
45	Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer. Cancers, 2020, 12, 886.	3.7	12
46	Effect of concurrent proton pump inhibitors (PPI) use in patients (pts) treated with immune checkpoint inhibitors (ICI) for metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2020, 38, 500-500.	1.6	2
47	The role of previous radical local treatment (RLT) on the outcome of immune checkpoint inhibitors (ICI) in patients (pts) with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2020, 38, 496-496.	1.6	0
48	AnÃ¡lisis de la expresiÃ³n nuclear de pSer727-STAT3 como factor pronÃ³stico en pacientes con carcinoma renal de cÃ©lulas claras. Actas UrolÃ³gicas EspaÃ±olas, 2020, 44, 245-250.	0.7	1
49	Terapia de privaciÃ³n de andrÃ³genos en pacientes con enfermedad localizada: comparaciÃ³n de las opciones de tratamiento y tiempo hasta la resistencia a la castraciÃ³n. Resultados del Registro EspaÃ±ol de CÃ¡ncer de PrÃ³stata. Actas UrolÃ³gicas EspaÃ±olas, 2020, 44, 156-163.	0.7	4
50	Serum Luteinizing Hormone Testing Can Identify Optimal Medical Castration. European Urology Open Science, 2020, 19, 24-26.	0.4	2
51	Replay by authors: Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 571.	1.6	0
52	Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?. European Urology Oncology, 2019, 2, 664-669.	5.4	23
53	A novel DNA-binding motif in prostate tumor overexpressed-1 (PTOV1) required for the expression of ALDH1A1 and CCNG2 in cancer cells. Cancer Letters, 2019, 452, 158-167.	7.2	2
54	Comparison of Outcomes between Standard and Palliative Management for High Grade Non-Muscle Invasive Bladder Cancer in Patients Older than 85 Years. Urologia Internationalis, 2019, 102, 277-283.	1.3	6

#	Article	IF	Citations
55	The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2019, 43, 118-123.	0.2	5
56	siRNA-silencing of CD40 attenuates unilateral ureteral obstruction-induced kidney injury in mice. PLoS ONE, 2019, 14, e0215232.	2.5	8
57	Reversal Unilateral Ureteral Obstruction: A Mice Experimental Model. Nephron, 2019, 142, 125-134.	1.8	12
58	Multiple immunofluorescence assay identifies upregulation of Active Î²-catenin in prostate cancer. BMC Research Notes, 2019, 12, 68.	1.4	1
59	Estudio comparativo de diferentes tÃ©cnicas quirÃºrgicas para el manejo del urÃ©ter distal durante la nefroureterectomÃa laparoscÃ³pica. Actas UrolÃ³gicas EspaÃ±olas, 2019, 43, 543-550.	0.7	0
60	Las biopsias de prÃ³stata dirigidas Â¿estÃ¡n listas para reemplazar las biopsias de prÃ³stata sistemÃ¡ticas?. Actas UrolÃ³gicas EspaÃ±olas, 2019, 43, 573-578.	0.7	3
61	La resonancia magnÃ©tica preoperatoria predice la recuperaciÃ³n temprana de la continencia urinaria tras la prostatectomÃa radical robÃ³tica. Actas UrolÃ³gicas EspaÃ±olas, 2019, 43, 137-142.	0.7	11
62	Valor de la proteÃna STAT3 como factor pronÃ³stico en el carcinoma renal de cÃ©lula clara. RevisiÃ³n sistemÃ¡tica. Actas UrolÃ³gicas EspaÃ±olas, 2019, 43, 118-123.	0.7	14
63	The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1?. Scandinavian Journal of Urology, 2019, 53, 21-25.	1.0	4
64	Micronuclei frequency in urothelial cells of bladder cancer patients, as a biomarker of prognosis. Environmental and Molecular Mutagenesis, 2019, 60, 168-173.	2.2	10
65	ComparaciÃ³n de los resultados perioperatorios de la cistectomÃa radical asistida por robot con derivaciÃ³n urinaria extracorpÃ³rea vs. intracorpÃ³rea. Actas UrolÃ³gicas EspaÃ±olas, 2019, 43, 277-283.	0.7	17
66	Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors.. Journal of Clinical Oncology, 2019, 37, 4531-4531.	1.6	5
67	Association among the R.E.N.A.L. nephrometry score and clinical outcomes in patients with small renal masses treated with percutaneous contrast enhanced ultrasound radiofrequency ablation. Central European Journal of Urology, 2019, 72, 92-99.	0.3	1
68	Variaciones de la prostatectomÃa radical para una recuperaciÃ³n de la continencia urinaria precoz: una revisiÃ³n sistemÃ¡tica. Actas UrolÃ³gicas EspaÃ±olas, 2019, 43, 526-535.	0.7	10
69	Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017. http://uroweb.org/guideline/prostate-cancer. European Urology, 2018, 73, e134-e135.	1.9	19
70	Estado actual de la ingenierÃa tisular aplicada a la reconstrucciÃ³n vesical en humanos. Actas UrolÃ³gicas EspaÃ±olas, 2018, 42, 435-441.	0.7	4
71	A systematic review of methods for quantifying serum testosterone in patients with prostate cancer who underwent castration. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2018, 42, 86-93.	0.2	1
72	FunciÃ³n cognitiva en pacientes tratados con supresiÃ³n androgÃ©nica: estudio prospectivo y multicÃ©ntrico. Actas UrolÃ³gicas EspaÃ±olas, 2018, 42, 114-120.	0.7	7

#	Article	IF	Citations
73	MÃ©todos para cuantificar la testosterona sÃ©rica en pacientes con cÃ¡ncer de prÃ³stata sometidos a castraciÃ³n: una revisiÃ³n sistemÃ¡tica. Actas UrolÃ³gicas EspaÃ±olas, 2018, 42, 86-93.	0.7	3
74	Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. Clinical Genitourinary Cancer, 2018, 16, e491-e496.	1.9	15
75	Low-dose statin treatment increases prostate cancer aggressiveness. Oncotarget, 2018, 9, 1494-1504.	1.8	15
76	Use of an acellular collagenâ€“elastin matrix to support bladder regeneration in a porcine model of peritoneocystoplasty. Central European Journal of Urology, 2018, 71, 353-359.	0.3	1
77	Under-expression of CK2Î² subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival. Oncotarget, 2018, 9, 5736-5751.	1.8	11
78	Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy. European Urology Focus, 2017, 3, 470-479.	3.1	4
79	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. Journal of Urology, 2017, 198, 817-823.	0.4	31
80	Systematic review of renal carcinoma prognostic factors. Actas UrolÃ³gicas EspaÃ±olas (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4	0.2	0
81	Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2017, 98, 590-594.	0.8	14
82	Radiofrecuencia percutÃ¡nea guiada por ecografÃa en el tratamiento de masas renales pequeÃ±as. Actas UrolÃ³gicas EspaÃ±olas, 2017, 41, 497-503.	0.7	3
83	Free Testosterone During Androgen Deprivation Therapy Predicts Castrationâ€Resistant Progression Better Than Total Testosterone. Prostate, 2017, 77, 114-120.	2.3	9
84	RevisiÃ³n sistemÃ¡tica de los factores pronÃ³sticos del carcinoma renal. Actas UrolÃ³gicas EspaÃ±olas, 2017, 41, 215-225.	0.7	11
85	Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients. Journal of Biomedical Science, 2017, 24, 81.	7.0	5
86	Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. Oncotarget, 2017, 8, 4960-4976.	1.8	80
87	The role of prostate tumor overexpressed 1 in cancer progression. Oncotarget, 2017, 8, 12451-12471.	1.8	9
88	Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells. Oncotarget, 2017, 8, 59165-59180.	1.8	15
89	Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. Orphanet Journal of Rare Diseases, 2016, 11, 128.	2.7	11
90	Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2016, 40, 477-484.	0.2	5

#	Article	IF	Citations
91	Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. Cancer Treatment Reviews, 2016, 50, 208-216.	7.7	19
92	Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy. International Journal of Urology, 2016, 23, 957-958.	1.0	14
93	Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer. Scandinavian Journal of Urology, 2016, 50, 425-428.	1.0	12
94	Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies. Prostate, 2016, 76, 1501-1506.	2.3	16
95	Cambios hormonales despuÃ©s del tratamiento de cÃ¡ncer de prÃ³stata localizado. ComparaciÃ³n entre radioterapia de haz externo y prostatectomÃa radical. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 549-555.	0.7	6
96	Utilidad del Ãndice RENAL â€“Radius; Exo/endophitic; Nearnes to sinus; Anterior/posterior; Location relative to polar linesâ€“ en el manejo de las masas renales. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 601-607.	0.7	6
97	Eficacia del Ãndice de salud prostÃ¡tica para identificar cÃ¡nceres de prÃ³stata agresivos. Una validaciÃ³n institucional. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 378-385.	0.7	12
98	DeterminaciÃ³n de la testosterona sÃ©rica durante la supresiÃ³n androgÃ©nica en pacientes con cÃ¡ncer de prÃ³stata: una revisiÃ³n sistemÃ¡tica. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 477-484.	0.7	10
99	Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer. Critical Reviews in Oncology/Hematology, 2016, 100, 127-136.	4.4	17
100	Patient-derived AVATAR mouse models to predict prognosis in advanced renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 551-551.	1.6	2
101	Identification of somatic gene mutations in penile squamous cell carcinoma. Genes Chromosomes and Cancer, 2015, 54, 629-637.	2.8	17
102	Clinical significance of proliferative inflammatory atrophy finding in prostatic biopsies. Prostate, 2015, 75, 1669-1675.	2.3	14
103	Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines. BioMed Research International, 2015, 2015, 1-11.	1.9	19
104	The Metabolic Syndrome and its Components in Patients with Prostate Cancer on Androgen Deprivation Therapy. Journal of Urology, 2015, 193, 1963-1969.	0.4	49
105	Implementing newer agents for the management of castrateâ€resistant prostate cancer: what is known and what is needed?. BJU International, 2015, 115, 364-372.	2.5	8
106	Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. British Journal of Cancer, 2015, 112, 468-474.	6.4	48
107	Comportamiento de la testosterona total y libre en suero como predictores del riesgo de cÃ¡ncer de prÃ³stata y de su agresividad. Actas UrolÃ³gicas EspaÃ±olas, 2015, 39, 573-581.	0.7	9
108	Urinary biomarkers for the detection of prostate cancer in patients with highâ€grade prostatic intraepithelial neoplasia. Prostate, 2015, 75, 1102-1113.	2.3	23

#	Article	IF	Citations
109	Behavior of total and free serum testosterone as a predictor for the risk of prostate cancer and its aggressiveness. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2015, 39, 573-581.	0.2	3
110	Effects of Holmium Laser Enucleation of the Prostate on Sexual Function. Journal of Endourology, 2015, 29, 332-339.	2.1	39
111	Renal cell carcinoma avatar mouse models for the personalized cancer therapy era.. Journal of Clinical Oncology, 2015, 33, e15627-e15627.	1.6	0
112	Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness. International Journal of Molecular Sciences, 2014, 15, 13615-13623.	4.1	25
113	The reproducibility and predictive value on outcome of renal biopsies from expanded criteria donors. Kidney International, 2014, 85, 1161-1168.	5.2	126
114	Bone health in patients with prostate cancer. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2014, 38, 685-693.	0.2	1
115	Cyclooxygenaseâ€2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU International, 2014, 113, E164-77.	2.5	20
116	Significado clÃnico de la atrofia proliferativa inflamatoria en la biopsia prostÃ¡tica. Actas UrolÃ³gicas EspaÃ±olas, 2014, 38, 122-126.	0.7	7
117	Current significance of the finding of high grade prostatic intraepithelial neoplasia in the prostate biopsy. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2014, 38, 270-275.	0.2	3
118	UreteropielostomÃa con vÃa nativa en el tratamiento de la uropatÃa obstructiva en el trasplante renal adulto. Experiencia y posibilidades tÃ©cnicas. Actas UrolÃ³gicas EspaÃ±olas, 2014, 38, 552-556.	0.7	1
119	Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?. Clinical and Translational Oncology, 2014, 16, 102-106.	2.4	7
120	HAVCR/KIM-1 Activates the IL-6/STAT-3 Pathway in Clear Cell Renal Cell Carcinoma and Determines Tumor Progression and Patient Outcome. Cancer Research, 2014, 74, 1416-1428.	0.9	76
121	Extensive emphysematous pyelonephritis in a renal allograft: case report and review of literature. Transplant Infectious Disease, 2014, 16, 642-647.	1.7	11
122	Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer. European Urology, 2014, 66, 655-663.	1.9	16
123	Salud Ã³sea en pacientes con cÃ¡ncer de prÃ³stata. Actas UrolÃ³gicas EspaÃ±olas, 2014, 38, 685-693.	0.7	1
124	Bone mass behavior after 1Âyear of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. Rheumatology International, 2014, 34, 1419-1425.	3.0	3
125	Maximal Testosterone Suppression in Prostate Cancerâ€"Free vs Total Testosterone. Urology, 2014, 83, 1217-1222.	1.0	16
126	Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressiveness. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2014, 38, 232-237.	0.2	11

#	Article	IF	Citations
127	Significado actual del hallazgo de la neoplasia intraepitelial prostÃ¡tica de alto grado en la biopsia prostÃ¡tica. Actas UrolÃ³gicas EspaÃ±olas, 2014, 38, 270-275.	0.7	4
128	Metabolic syndrome in patients with prostate cancer undergoing androgen suppression. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2014, 38, 285-289.	0.2	2
129	Sedentarismo y sobrepeso como factores de riesgo en la detecciÃ³n del cÃ¡ncer de prÃ³stata y su agresividad. Actas UrolÃ³gicas EspaÃ±olas, 2014, 38, 232-237.	0.7	16
130	SÃndrome metabÃ³lico en pacientes con cÃ¡ncer de prÃ³stata sometidos a supresiÃ³n androgÃ©nica. Actas UrolÃ³gicas EspaÃ±olas, 2014, 38, 285-289.	0.7	4
131	CÃ¡ncer de prÃ³stata resistente a castraciÃ³n no diseminado (CPRCM0), un viejo escenario con interÃ©s clÃnico renovado. Actas UrolÃ³gicas EspaÃ±olas, 2014, 38, 419-420.	0.7	0
132	Role of Immunotherapy in Castrationâ€Resistant Prostate Cancer (<scp>CRPC</scp>). BJU International, 2014, 113, 367-375.	2.5	7
133	Genetic predisposition to early recurrence in clinically localized prostate cancer. BJU International, 2013, 111, 549-558.	2.5	17
134	Denosumab and Bone Metastasisâ€“Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time. Journal of Clinical Oncology, 2013, 31, 3800-3806.	1.6	196
135	Hepatitis A virus cellular receptor 1/kidney injury molecule-1 is a susceptibility gene for clear cell renal cell carcinoma and hepatitis A virus cellular receptor/kidney injury molecule-1 ectodomain shedding a predictive biomarker of tumour progression. European Journal of Cancer, 2013, 49, 2034-2047.	2.8	23
136	Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU International, 2013, 111, 1031-1036.	2.5	54
137	Estado actual del trasplante renal en bloque de donante pediÃ¡trico en receptor adulto joven. Actas UrolÃ³gicas EspaÃ±olas, 2013, 37, 383-386.	0.7	5
138	The role of prostate-specific antigen in light of new scientific evidence. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2013, 37, 324-329.	0.2	2
139	Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2013, 37, 292-304.	0.2	7
140	Papel del antÃgeno prostÃ¡tico especÃfico ante las nuevas evidencias cientÃficas. Actas UrolÃ³gicas EspaÃ±olas, 2013, 37, 324-329.	0.7	6
141	Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: Correlation with pathologic subtypes, p16INK4a expression, and prognosis. Journal of the American Academy of Dermatology, 2013, 68, 73-82.	1.2	91
142	Avances en la prevenciÃ³n y el tratamiento de las metÃ¡stasis Ã³seas en cÃ¡ncer de prÃ³stata. Papel de la inhibiciÃ³n de RANK/RANKL. Actas UrolÃ³gicas EspaÃ±olas, 2013, 37, 292-304.	0.7	12
143	Molecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues. BioMed Research International, 2013, 2013, 1-15.	1.9	12
144	The Present and Future of Prostate Cancer Urine Biomarkers. International Journal of Molecular Sciences, 2013, 14, 12620-12649.	4.1	56

#	Article	IF	Citations
145	Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. British Journal of Cancer, 2013, 109, 121-130.	6.4	19
146	Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. British Journal of Cancer, 2013, 108, 2565-2572.	6.4	31
147	Analysis of the Lipid Profile and Atherogenic Risk during Androgen Deprivation Therapy in Prostate Cancer Patients. Urologia Internationalis, 2013, 90, 41-44.	1.3	26
148	C-MYC, HER2, and HER3 expression in localized prostate cancer (PC) treated with radical radiotherapy: Modulation by statins use and correlation with time to progression.. Journal of Clinical Oncology, 2013, 31, e16045-e16045.	1.6	0
149	Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet, The, 2012, 379, 39-46.	13.7	716
150	Recommendations on the management of controversies in advanced castrate-resistant prostate cancer. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2012, 36, 569-577.	0.2	3
151	Re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. Eur Urol 2012;61:378â€“84. European Urology, 2012, 61, e53-e54.	1.9	2
152	Skeletal complications of ADT: disease burden and treatment options. Asian Journal of Andrology, 2012, 14, 670-675.	1.6	4
153	Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics.. Journal of Clinical Oncology, 2012, 30, 6-6.	1.6	12
154	Holmium Laser Enucleation of the Prostate. Videourology (New Rochelle, N Y), 2012, 26, .	0.1	0
155	Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics.. Journal of Clinical Oncology, 2012, 30, 4510-4510.	1.6	7
156	2321 COMPARATIVE ANALYSIS OF PROSTATE CANCER ANTIGEN 3 MRNA EXPRESSION IN BENIGN PERIPHERAL PROSTATIC TISSUE, CANCER AND ISOLATED OR CANCER-ASSOCIATED HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA. Journal of Urology, 2011, 185, .	0.4	1
157	Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2011, 35, 232-239.	0.2	4
158	Re: Endo et al.: Anteroposterior Dissection HoLEP: A Modification to Prevent Transient Stress Urinary Incontinence (Urology 2010;76:1451-1455). Urology, 2011, 77, 255-256.	1.0	0
159	Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome. BJU International, 2011, 108, E71-6.	2.5	31
160	Prostate cancer in Spain: from guidelines to clinical practice. BJU International, 2011, 108, 61-66.	2.5	16
161	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multiâ€institutional study. BJU International, 2011, 108, 24-30.	2.5	111
162	Antihypertensive Drugs and the Risk of Prostate Cancer. European Urology, 2011, 60, 1309-1310.	1.9	2

#	Article	IF	Citations
163	PTOV1 is overexpressed in human high-grade malignant tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 323-330.	2.8	22
164	33% radius evaluation to assess bone mineral density in prostate cancer patients. World Journal of Urology, 2011, 29, 815-819.	2.2	4
165	Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches. Current Oncology Reports, 2011, 13, 216-221.	4.0	48
166	A Threeâ€Gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate, 2011, 71, 1736-1745.	2.3	43
167	PÃ©rdida de masa Ã³sea en pacientes con cÃ¡ncer de prÃ³stata sometidos a deprivaciÃ³n androgÃ©nica. Actas UrolÃ³gicas EspaÃ±olas, 2011, 35, .	0.7	1
168	Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. World Journal of Urology, 2010, 28, 677-680.	2.2	25
169	Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment. Clinical and Translational Oncology, 2010, 12, 346-355.	2.4	6
170	Re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659â€“68. European Urology, 2010, 57, e1.	1.9	1
171	Testosterone Measurement in Patients with Prostate Cancer. European Urology, 2010, 58, 65-74.	1.9	41
172	Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). Prostate, 2010, 70, 1044-1053.	2.3	49
173	A transcriptional signature associated with the onset of benign prostate hyperplasia in a canine model. Prostate, 2010, 70, 1402-1412.	2.3	7
174	PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate, 2010, 70, 1760-1767.	2.3	63
175	Risk factors for positive findings in patients with highâ€grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmetteâ€GuÃ©rin therapy and the decision for a repeat TUR. BJU International, 2010, 105, 202-207.	2.5	36
176	Evaluation of the serum testosterone to prostateâ€specific antigen ratio as a predictor of prostate cancer risk. BJU International, 2010, 105, 481-484.	2.5	24
177	Preoperative Prediction of Pathologically Insignificant Prostate Cancer in Radical Prostatectomy Specimens: The Role of Prostate Volume and the Number of Positive Cores. Urologia Internationalis, 2010, 84, 153-158.	1.3	15
178	858 AXIAL VERSUS PERIPHERAL DXA SCAN TO ASSES OSTEOPOROSIS IN PROSTATE CANCER PATIENTS. Journal of Urology, 2010, 183, .	0.4	1
179	Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. European Urology Supplements, 2010, 9, 675-691.	0.1	19
180	Improved Prediction of Biochemical Recurrence After Radical Prostatectomy by Genetic Polymorphisms. Journal of Urology, 2010, 184, 506-511.	0.4	28

#	Article	IF	Citations
181	Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis. Experimental Cell Research, 2009, 315, 3004-3013.	2.6	30
182	Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2008;54:303â€“14. European Urology, 2009, 55, e15-e16.	1.9	15
183	Identification, characterization and expression of novel Sex Hormone Binding Globulin alternative first exons in the human prostate. BMC Molecular Biology, 2009, 10, 59.	3.0	11
184	Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU International, 2009, 103, 332-335.	2.5	58
185	The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU International, 2009, 104, 486-489.	2.5	40
186	Alendronate decreases the fracture risk in patients with prostate cancer on androgenâ€deprivation therapy and with severe osteopenia or osteoporosis. BJU International, 2009, 104, 1637-1640.	2.5	36
187	Immunolocalization of Androgen Receptors, Estrogen Â Receptors, and Estrogen Â Receptors in Experimentally Induced Canine Prostatic Hyperplasia. Journal of Andrology, 2009, 30, 240-247.	2.0	11
188	Is there a relationship between prostate volume and Gleason score?. BJU International, 2008, 102, 563-565.	2.5	8
189	PTOV1 Expression Predicts Prostate Cancer in Men with Isolated High-Grade Prostatic Intraepithelial Neoplasia in Needle Biopsy. Clinical Cancer Research, 2008, 14, 2617-2622.	7.0	48
190	Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer. Urology, 2007, 69, 500-504.	1.0	159
191	Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy. Journal of Urology, 2007, 178, 1290-1295.	0.4	242
192	25 THE SERUM TESTOSTERONE CASTRATION LEVEL WITH CLINICAL RELEVANCE. European Urology Supplements, 2007, 6, 29.	0.1	3
193	The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU International, 2007, 99, 812-816.	2.5	50
194	Expression of Androgen, Oestrogen Î± and Î², and Progesterone Receptors in the Canine Prostate: Differences between Normal, Inflamed, Hyperplastic and Neoplastic Glands. Journal of Comparative Pathology, 2007, 136, 1-8.	0.4	26
195	Ultrastructural Changes in Prostate Cells During Hormone-induced Canine Prostatic Hyperplasia. Ultrastructural Pathology, 2006, 30, 435-442.	0.9	5
196	Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen Suppression. Journal of Urology, 2006, 175, 1679-1683.	0.4	90
197	Correlation Between the Biopsies in Marginal Donor Kidneys for Transplantation: Is It Necessary to Biopsy Both Kidneys?. Transplantation Proceedings, 2006, 38, 1270-1273.	0.6	4
198	Case report: Retroperitoneal fibrosis simulating local relapse of sarcomatoid renal cell carcinoma. International Urology and Nephrology, 2006, 38, 463-465.	1.4	6

#	Article	IF	Citations
199	Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer. Urologia Internationalis, 2006, 77, 135-138.	1.3	64
200	Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histology and Histopathology, 2006, 21, 857-65.	0.7	80
201	Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer. Anti-Cancer Drugs, 2005, 16, 863-866.	1.4	13
202	Behavior of free Testosterone in Patients with Prostate Cancer on Androgen Deprivation Therapy. International Journal of Biological Markers, 2005, 20, 119-122.	1.8	9
203	Usefulness of Prostate-Specific Antigen Nadir as Predictor of Androgen-Independent Progression of Metastatic Prostate Cancer. International Journal of Biological Markers, 2005, 20, 209-216.	1.8	16
204	PTOV1 Enables the Nuclear Translocation and Mitogenic Activity of Flotillin-1, a Major Protein of Lipid Rafts. Molecular and Cellular Biology, 2005, 25, 1900-1911.	2.3	86
205	Gastric Cancer in Augmentation Gastrocystoplasty. Urologia Internationalis, 2005, 74, 368-370.	1.3	21
206	Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. International Journal of Biological Markers, 2005, 20, 119-222.	1.8	7
207	Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. International Journal of Biological Markers, 2005, 20, 119-22.	1.8	5
208	Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. Kidney International, 2004, 65, 1761-1773.	5.2	32
209	Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. International Journal of Cancer, 2004, 108, 877-881.	5.1	50
210	CuantificaciÃ³n de la isoforma compleja del antÃgeno prostÃ¡tico especÃfico (PSAc). Un nuevo reto en la era PSA. Medicina ClÃnica, 2004, 122, 256-258.	0.6	0
211	Osteoporosis during Continuous Androgen Deprivation: Influence of the Modality and Length of Treatment. European Urology, 2003, 44, 661-665.	1.9	56
212	PTOV-1, a Novel Protein Overexpressed in Prostate Cancer, Shuttles between the Cytoplasm and the Nucleus and Promotes Entry into the S Phase of the Cell Division Cycle. American Journal of Pathology, 2003, 162, 897-905.	3.8	49
213	Analysis of Bone Alkaline Phosphatase as a Marker for the Diagnosis of Osteoporosis in Men under Androgen Ablation. International Journal of Biological Markers, 2003, 18, 290-294.	1.8	3
214	Analysis of bone alkaline phosphatase as a marker for the diagnosis of osteoporosis in men under androgen ablation. International Journal of Biological Markers, 2003, 18, 290-294.	1.8	0
215	Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer. Urology, 2002, 59, 277-280.	1.0	16
216	Value of Percent Free Prostate-Specific Antigen for the Prediction of Pathological Stage in Men with Clinically Localized Prostate Cancer. International Journal of Biological Markers, 2002, 17, 239-243.	1.8	0

#	Article	IF	Citations
217	Value of Percent Free Prostate-Specific Antigen for the Prediction of Pathological Stage in Men with Clinically Localized Prostate Cancer. International Journal of Biological Markers, 2002, 17, 239-243.	1.8	5
218	Bone Alkaline Phosphatase Serum Level Predicts the Response to Antiandrogen Withdrawal. European Urology, 2002, 41, 257-261.	1.9	3
219	The Percentage of Free Prostatic-Specific Antigen Is Also Useful in Men with Normal Digital Rectal Examination and Serum Prostatic-Specific Antigen between 10.1 and 20 ng/ml. European Urology, 2002, 42, 333-337.	1.9	15
220	Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer. International Journal of Biological Markers, 2002, 17, 239-243.	1.8	5
221	The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer. BJU International, 2001, 83, 1003-1006.	2.5	14
222	PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks. Oncogene, 2001, 20, 1455-1464.	5.9	61
223	Use of Percent Free Prostate–Specific Antigen as a Predictor of the Pathological Features of Clinically Localized Prostate Cancer. European Urology, 2000, 38, 225-229.	1.9	13
224	Prediction of Prostate Volume Based on Total and Free Serum Prostate–Specific Antigen: Is It Reliable?. European Urology, 2000, 38, 91-95.	1.9	36
225	Effect of Inflammation and Benign Prostatic Enlargement on Total and Percent Free Serum Prostatic Specific Antigen. European Urology, 2000, 37, 537-540.	1.9	87
226	Effect of High–Grade Prostatic Intraepithelial Neoplasia on Total and Percent Free Serum Prostatic–Specific Antigen. European Urology, 2000, 37, 456-459.	1.9	14
227	Value of Routine Transition Zone Biopsies in Patients Undergoing Ultrasound-Guided Sextant Biopsies for the First Time. European Urology, 1999, 35, 294-297.	1.9	48
228	Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 625-632.	6.4	139
229	Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. , 1999, 84, 421-425.		67
230	Intraindividual Variations of Total and Percent Free Serum Prostatic-Specific Antigen Levels in Patients with Normal Digital Rectal Examination. European Urology, 1999, 36, 111-115.	1.9	19
231	Influence of highâ€grade prostatic intraâ€epithelial neoplasia on total and percentage free serum prostatic specific antigen. BJU International, 1999, 84, 657-660.	2.5	9
232	Individual variations of total and percent free serum prostatic specific antigen: could they change the indication of prostatic biopsy?. Oncology Reports, 1999, 6, 887-90.	2.6	6
233	Over-expression of epidermal growth factor receptor and c-erbB2/neu but not ofint-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR. , 1998, 76, 464-467.		18
234	Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependent EGFr mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride. , 1998, 76, 519-522.		8

#	Article	IF	Citations
235	Comparison of Percent Free Prostate Specific Antigen and Prostate Specific Antigen Density as Methods to Enhance Prostate Specific Antigen Specificity in Early Prostate Cancer Detection in Men With Normal Rectal Examination and Prostate Specific Antigen Between 4.1 and 10 ng./ml.. Journal of Urology, 1997, 158, 502-504.	0.4	64
236	Measurement of free PSA in the diagnosis and staging of prostate cancer. , 1997, 71, 756-759.		21
237	Measurement of free PSA in the diagnosis and staging of prostate cancer. International Journal of Cancer, 1997, 71, 756-759.	5.1	1
238	Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. Journal of Urology, 1997, 158, 502-4.	0.4	9
239	Clinical Efficacy of Bone Alkaline Phosphatase and Prostate Specific Antigen in the Diagnosis of Bone Metastasis in Prostate Cancer. Journal of Urology, 1996, 155, 1348-1351.	0.4	66
240	Prostate carcinoma staging: Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Cancer, 1996, 78, 2374-2378.	4.1	19
241	Prostate carcinoma staging: Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Cancer, 1996, 78, 2374-2378.	4.1	1
242	M-CAVI, A Neoadjuvant Carboplatin-based Regimen for the Treatment of T2-4N0M0 Carcinoma of the Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 344-348.	1.3	14
243	Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. Journal of Urology, 1996, 155, 1348-51.	0.4	14
244	Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Cancer, 1996, 78, 2374-8.	4.1	1
245	Impact of kidney and liver metabolism on serum prostate specific antigen levels. International Journal of Biological Markers, 1995, 10, 236-237.	1.8	0
246	Behavior of Bone Alkaline Phosphatase (BAP) Determined with Immunoradiometric Assay in Metastatic Prostate Cancer. International Journal of Biological Markers, 1994, 9, 145-145.	1.8	2
247	Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer, 1992, 70, 1974-1979.	4.1	53
248	Elevated serum PSA and acute bacterial prostatitis. Urology, 1990, 35, 373.	1.0	4
249	Bone Marrow Prostatic Specific Antigen and Prostatic Acid Phosphatase Levels: Are They Helpful in Staging Prostatic Cancer. Journal of Urology, 1987, 137, 891-893.	0.4	6